Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
1. A method of treating cancer comprising a FLT3 mutation in a subject in need of such treatment, the method comprising the step of administering an antibody drug conjugate (ADC) and an FLT3 inhibitor, wherein the ADC comprises a PBD cytotoxic agent and an antibody, wherein the FLT-3 inhibitor is quizartinib, and wherein the antibody is: 1) h2H12 that specifically binds to a human CD33 protein; or 2) h7G3 that specifically binds to a human CD123 protein.
2. The method of claim 1 , wherein the PBD cytotoxic agent has the formula
3. The method of claim 2 , wherein the antibody is h2H12 that specifically binds to a human CD33 protein.
4. The method of claim 2 , wherein the antibody is h7G3 that specifically binds to a human CD123 protein.
5. A method of treating cancer in a subject in need of such treatment, the method comprising the step of administering an antibody drug conjugate (ADC) and an FLT3 inhibitor, wherein the ADC comprises a PBD cytotoxic agent and an antibody, wherein the FLT3 inhibitor is quizartinib, wherein the cancer cell has a FLT3 mutation that results in decreased FLT3 expression or function as compared to a reference cell from the subject that does not have the FLT3 mutation, and wherein the antibody is: 1) h2H12 that specifically binds to a human CD33 protein; or 2) h7G3 that specifically binds to a human CD123 protein.
6. The method of claim 5 , wherein the PBD cytotoxic agent has the formula
7. The method of claim 5 , wherein the antibody h2H12 that specifically binds to a human CD33 protein.
8. The method of claim 5 , wherein the antibody is h7G3 that specifically binds to a human CD123 protein.